# A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis

> **NCT07747480** · PHASE1 · NOT_YET_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 16 (estimated)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **BIOLOGICAL:** Aletekitug

## Key facts

- **NCT ID:** NCT07747480
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-10
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-12-04
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07747480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07747480, "A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07747480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*